Certara, Inc. (NASDAQ:CERT – Get Free Report) traded up 7% during mid-day trading on Friday. The company traded as high as $9.27 and last traded at $9.2450. 1,910,498 shares changed hands during trading, a decline of 45% from the average session volume of 3,503,389 shares. The stock had previously closed at $8.64.
Analyst Ratings Changes
Several brokerages recently weighed in on CERT. Weiss Ratings raised shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. UBS Group restated a “neutral” rating and issued a $10.00 target price on shares of Certara in a report on Wednesday, September 30th. Finally, Barclays upped their price target on Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.60.
Check Out Our Latest Stock Analysis on CERT
Certara Stock Performance
Certara (NASDAQ:CERT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business’s revenue was down 10.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.07 earnings per share. As a group, sell-side analysts expect that Certara, Inc. will post 0.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Certara
Several institutional investors have recently added to or reduced their stakes in CERT. GAMMA Investing LLC boosted its stake in Certara by 21.2% in the third quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock valued at $90,000 after acquiring an additional 1,710 shares during the last quarter. Sequoia Financial Advisors LLC increased its stake in shares of Certara by 12.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock worth $117,000 after purchasing an additional 1,923 shares during the last quarter. NorthRock Partners LLC bought a new stake in shares of Certara in the 2nd quarter worth approximately $68,000. Integrated Wealth Concepts LLC purchased a new position in Certara in the second quarter valued at approximately $39,000. Finally, Corient Private Wealth LP lifted its stake in Certara by 166.8% in the second quarter. Corient Private Wealth LP now owns 74,316 shares of the company’s stock valued at $487,000 after purchasing an additional 46,462 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.
About Certara
Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.
Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.
Read More
- Five stocks we like better than Certara
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
